Addiction
1949–1970 · 1 of 4
Medicalization of Addiction
1949–1970
Substance Use DisorderSubstance UseSubstance AbuseAddictive BehaviorAddiction MedicineAlcohol (Drug)Substance AddictionAlcohol DependenceAlcohol AbuseMental Health
The period saw addiction research increasingly framed as a medical disease, reframing treatment, research, and policy around standardized diagnoses and biomedical concepts. Simultaneously, reinforcement theory and early behavioral models established relapse cycles as central treatment endpoints, guiding contingency management approaches. Neuropharmacology and biobehavioral studies linked drug effects to brain monoamines and serotonin, while standardized inventories such as psychometric scales and drug-effect measures provided quantifiable phenotypes. Methodological threads—psychometrics, long-term follow-ups, and animal models of conditioning—began to operationalize addiction phenotypes and prognosis, setting the stage for protracted recovery narratives.
1971–2000
Substance Use DisorderSubstance AbuseSubstance UseAddictive BehaviorAddiction MedicineSubstance AddictionAlcohol (Drug)Mental HealthAddiction BiologyAlcohol Abuse
The period centers on a dopamine-centered incentive-sensitization framework that links craving and motivational drive to mesolimbic dopamine dynamics, while neuroadaptive cascades in signaling pathways unify chronic drug action and individual vulnerability. Relapse and withdrawal emerge as core experimental constructs, with behavioral pharmacology guiding models of relapse, extinction, and reinstatement, and clinical pharmacotherapy oriented toward craving states and receptor targets. Developmental risk framing highlights adolescence and early adulthood as vulnerable periods informing prevention and early intervention.
This era consolidated craving neuroscience as a central paradigm, yielding widely adopted screening tools and motivational approaches that shaped prevention and treatment practice. Foundational works introduced and refined the craving incentive framework and the integration of pharmacological and behavioral strategies, bridging molecular mechanisms with clinical outcomes and policy implications.
2001–2014
Substance Use DisorderSubstance UseSubstance AbuseAddictive BehaviorMental HealthAddiction MedicineSubstance AddictionAlcohol (Drug)Addiction BiologyAddiction Treatment
During 2001–2014, addiction research coalesced around frontostriatal neurocircuitry as a core driver of addictive behavior, with neuroimaging revealing impaired prefrontal control and altered ventral-to-dorsal striatal signaling that underlies craving, decision-making, and compulsivity. Dopamine dynamics and glutamatergic drive from prefrontal regions were shown to recruit dorsal striatal circuits during cue-evoked craving and relapse, linking animal reinstatement models with human imaging. Population-level epidemiology and DSM-based measures clarified prevalence and disability while neuroplastic changes in dopamine and glutamate systems highlighted the persistence of compulsive drug-seeking.
The period solidified a circuit-based paradigm, emphasizing relapse circuits as central targets and integrating translational neuroscience with public health data to shape prevention and treatment strategies.
2015–2023
Substance Use DisorderSubstance UseSubstance AbuseAddictive BehaviorMental HealthAddiction MedicineSubstance AddictionAlcohol (Drug)Opioid Use DisorderAddiction Biology
The period integrated neurobiological accounts of addiction with population health perspectives, emphasizing brain reward circuitry, neuroadaptations, and circuit-level analyses that incorporate endocannabinoid signaling and neuromodulation effects on drug-seeking behavior. Cannabinoid research widened from therapeutic use and risk assessment to population-level implications, linking pharmacology with perceived public health impact. Overdose epidemiology and prescribing guidelines highlighted the policy-sensitive interface between clinical practice standards and public health surveillance, while alcohol use disorder studies connected epidemiological measurement with disability burden across populations.
The synthesis reframed addiction as a brain circuitry disease that informs pharmacotherapy, behavioral interventions, and public health strategies; this paradigm shift steered research priorities, advanced translational approaches, and supported global assessments of burden and risk across diverse populations.